Log in

TransMedics Group Stock Forecast, Price & News

-0.40 (-3.07 %)
(As of 10/28/2020 12:00 AM ET)
Today's Range
Now: $12.65
50-Day Range
MA: $14.42
52-Week Range
Now: $12.65
Volume102,039 shs
Average Volume170,052 shs
Market Capitalization$343.51 million
P/E RatioN/A
Dividend YieldN/A
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion apparatus, optimization, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:TMDX



Sales & Book Value

Annual Sales$23.60 million
Book Value$2.58 per share


Net Income$-33,550,000.00
Net Margins-143.93%


Market Cap$343.51 million
Next Earnings Date11/4/2020 (Confirmed)
OptionableNot Optionable
-0.40 (-3.07 %)
(As of 10/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

How has TransMedics Group's stock price been impacted by COVID-19?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TMDX shares have decreased by 7.1% and is now trading at $12.65.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of TransMedics Group?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TransMedics Group

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for TransMedics Group

How can I listen to TransMedics Group's earnings call?

TransMedics Group will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) issued its earnings results on Wednesday, August, 5th. The company reported ($0.36) EPS for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.06. The firm had revenue of $3.39 million for the quarter, compared to analysts' expectations of $3.24 million. TransMedics Group had a negative return on equity of 49.98% and a negative net margin of 143.93%.
View TransMedics Group's earnings history

What price target have analysts set for TMDX?

5 Wall Street analysts have issued 12 month target prices for TransMedics Group's shares. Their forecasts range from $15.00 to $28.00. On average, they expect TransMedics Group's stock price to reach $21.20 in the next year. This suggests a possible upside of 67.6% from the stock's current price.
View analysts' price targets for TransMedics Group

Are investors shorting TransMedics Group?

TransMedics Group saw a decrease in short interest during the month of October. As of October 15th, there was short interest totaling 960,900 shares, a decrease of 39.9% from the September 30th total of 1,600,000 shares. Based on an average daily trading volume, of 180,100 shares, the short-interest ratio is currently 5.3 days.
View TransMedics Group's Short Interest

Who are some of TransMedics Group's key competitors?

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and The Walt Disney (DIS).

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:
  • Dr. Waleed H. Hassanein, Founder, CEO, Pres & Director (Age 52, Pay $808.82k)
  • Mr. Stephen Gordon, CFO. Treasurer & Sec. (Age 52, Pay $491.92k)
  • Dr. Tamer I. Khayal, Chief Commercial Officer (Age 51, Pay $522.52k)
  • Mr. John F. Carey, VP of Operations (Age 55)
  • Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 49)

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by many different retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.40%), Taylor Wealth Management Partners (0.30%) and Cadence Capital Management LLC (0.06%). Company insiders that own TransMedics Group stock include David Weill, Edwin M Kania Jr, John F Carey, Stephen Gordon and Tamer I Khayal.
View institutional ownership trends for TransMedics Group

Which institutional investors are selling TransMedics Group stock?

TMDX stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC. Company insiders that have sold TransMedics Group company stock in the last year include John F Carey, Stephen Gordon, and Tamer I Khayal.
View insider buying and selling activity for TransMedics Group

Which institutional investors are buying TransMedics Group stock?

TMDX stock was bought by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, and Taylor Wealth Management Partners. Company insiders that have bought TransMedics Group stock in the last two years include David Weill, and Edwin M Kania Jr.
View insider buying and selling activity for TransMedics Group

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $12.65.

How big of a company is TransMedics Group?

TransMedics Group has a market capitalization of $343.51 million and generates $23.60 million in revenue each year. The company earns $-33,550,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. TransMedics Group employs 109 workers across the globe.

What is TransMedics Group's official website?

The official website for TransMedics Group is www.transmedics.com.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.